98%
921
2 minutes
20
Objective: To assess knowledge about HPV and HPV vaccine, willingness to have their daughters receive HPV vaccine, and factors associated with knowledge and willingness among parents of females 9 to 18 years of age in China.
Methods: We conducted a cross-sectional survey of parents with daughters 9 to 18 years of age in four provinces of China using a self-administered questionnaire. We used multivariable regression analyses to determine factors associated with willingness vaccinate.
Results: We received completed surveys from 5,215 parents. Among respondents, 846 (16.24 %) had a high level of knowledge about HPV (total score ≥ 5). High level of HPV knowledge was associated with having daughters who were <15 years old; having experience paying out-of-pocket for other vaccines; being a mother; having higher educational achievement; being a medical staff member; being in a higher-income category; and residing in an urban area. There were 2,419 (46.39 %) parents who were willing to vaccinate their daughter against HPV and 2,757 (52.87 %) who were willing to receive vaccine themselves (for female respondents) or indicated willingness of their spouse to be vaccinated (for male respondents). Willingness of mothers to be vaccinated was associated with daughters' age being greater than 14 years; having previously purchased self-paid vaccines; having higher educational achievement; being in a higher-income category; having a higher level of knowledge; and residing in an urban area. Parental willingness to vaccinate daughters was associated with daughters' age being greater than 14 years, age of parents younger 40, a history of purchasing self-paid vaccines; higher educational achievement; having a higher level of knowledge; being willing to receive HPV vaccine (themselves or their spouse); and residing in an urban area.
Conclusions: Level of knowledge and willingness to have daughters vaccinated with HPV vaccine are low among Chinese parents. For universal HPV vaccination of females 9-18 years of age, it is necessary to educate parents about HPV and HPV vaccine, and to reduce the price of HPV vaccine.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2022.11.016 | DOI Listing |
J Med Virol
September 2025
Department of Gynaecology, Shandong Provincial Third Hospital, Shandong University, Jinan, Shandong, China.
Persistent high-risk human papillomavirus (HPV) infection is a leading cause of cervical cancer worldwide. While prophylactic vaccines exist, many women remain at risk due to prior exposure or limited access to vaccination. Current treatments focus on ablating visible lesions but often fail to clear the virus completely.
View Article and Find Full Text PDFCancer Epidemiol
September 2025
Laboratory of Molecular and Cellular Biology of Cancer, CáncerLab, Department of Biomedical Sciences, Faculty of Medicine, Universidad Católica del Norte, Coquimbo, Chile. Electronic address:
Background: Cervical cancer is primarily caused by the Human Papillomavirus (HPV). Despite all the advances in early detection of HPV infection, cervical cancer remains one of the most common types of cancer in women, with a high presence in Latin America. We previously reported on the prevalence of HPV in the Coquimbo region, so the objective of this study was to determine the frequency of HPV in women in the Antofagasta and Arica regions of northern Chile.
View Article and Find Full Text PDFHealth Expect
October 2025
Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Introduction: Despite high coverage of routine childhood vaccines, uptake of the human papillomavirus (HPV) vaccine in the Pacific Island nation of Tonga has been slow. Culturally appropriate communication resources on the importance, safety, and effectiveness of the HPV vaccine are critical to support acceptance and uptake. To develop these resources, it is important to understand what people want to know.
View Article and Find Full Text PDFBiosens Bioelectron
September 2025
Materials Artificial Intelligence Center, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China. Electronic address:
Screening for high-risk human papillomavirus (hrHPV) infection is essential for cervical cancer prevention. However, developing a simple, portable, and low-cost hrHPV genotyping method remains challenging, particularly in resource-limited settings. Herein, we present an innovative amplification-free, point-of-care hrHPV genotyping platform integrating CRISPR/Cas12a with alkaline phosphatase (ALP)-mediated surface plasmon effect.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
September 2025
Aberdeen Centre for Women's Health Research (ACWHR), Institute Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, United Kingdom. Electronic address:
Background: Human papillomavirus (HPV) vaccination has reduced rates of cervical cancer. Research suggests that women with HPV, precancerous disease, and prior invasive treatments are at increased risk of preterm birth. This study aimed to determine if there is a reduction in adverse obstetric outcomes for HPV vaccinated women.
View Article and Find Full Text PDF